Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Key claim: A prospective multicenter RCT is planned to evaluate luspatercept, a TGF-β superfamily signaling modulator, for preventing poor erythroid engraftment after allogeneic HSCT in hematological malignancies with moderate-to-severe myelofibrosis.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with moderate to severe myelofibrosis (MF). Currently, there is a lack of effective prevention strategies for poor erythroid engraftment after transplantation. Luspatercept, a novel TGF-β superfamily signaling pathway modulator, has shown potential in small-sample studies for the treatment and prevention of post-transplant anemia. Given the high proportion and poor prognosis of poor engraftment function in hematological malignancies with moderate to severe myelofibrosis after transplantation, we plan to conduct a prospective, multicenter, randomized controlled study to explore the efficacy and safety of luspatercept in preventing poor erythroid engraftment after allo-HSCT in hematological malignancies with moderate to severe myelofibrosis.
Why this matters
Poor erythroid engraftment is a recognized but under-addressed complication of allo-HSCT in myelofibrosis, where residual marrow fibrosis and TGF-β–driven dyserythropoiesis impede red-cell recovery. A randomized trial of luspatercept introduces TGF-β superfamily modulation into the peri-transplant MF toolkit, which has otherwise been dominated by JAK inhibitors — opening a mechanistically distinct lever for improving transplant outcomes in this population.